UBE (4208) Q3 2025 earnings summary

Executive summary

• Net sales for 3Q FY2024 rose 8.0% year-over-year to ¥359.6B, driven by higher elastomer prices and recovery in nylon polymers and caprolactam sales overseas.

• Operating profit fell 22.5% year-over-year to ¥9.5B, impacted by weak specialty products, acquisition expenses, and impairment losses.

• Ordinary profit dropped 44.0% year-over-year to ¥13.0B, affected by extraordinary losses and lower non-operating income.

• Net loss attributable to owners was ¥19.1B, reversing a ¥19.9B profit last year, mainly due to a ¥30.3B impairment loss.

• Segment reclassification: UBE America Inc. and UBE CORPORATION AMERICA INC. moved from "Others" to "Polymers & Chemicals" from FY2024.

Financial highlights

• Net sales increased by ¥26.7B year-over-year, mainly from Polymers & Chemicals (+¥28.9B), offset by declines in Machinery and Others.

• Gross profit increased to ¥63.6B from ¥60.1B year-over-year.

• Operating profit decreased by ¥2.8B, with Specialty Products and Others segments seeing declines, while Machinery improved.

• Extraordinary losses of ¥36.0B, including dissolution-related and impairment losses, led to a net loss for the period.

• Cash flows from operating activities dropped to ¥5.4B (from ¥34.8B), while investing outflows increased to ¥57.4B, resulting in negative free cash flow.

Outlook and guidance

• FY2024 full-year net sales forecast revised down to ¥490.0B (from ¥510.0B), with operating profit forecast at ¥16.0B, down 28.7% year-over-year.

• Net loss attributable to owners forecast at ¥17.5B for FY2024, reversing a ¥29.0B profit in FY2023.

• Downward revisions reflect lower sales volumes in Polymers & Chemicals and Machinery, and extraordinary losses.

• Dividend forecast raised to ¥110/share (up ¥5), maintaining a policy of consistent shareholder returns.

• Ordinary profit forecast at ¥20.0B, down 45.0% year-over-year.